Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Interactions with Lenacapavir

Tuesday 11 October 2022

Lenacapavir (Sunlenca®) is now included in the list of HIV therapies. Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (CA) subunits. Initiation of treatment with lenacapavir requires tablets to be taken as oral loading prior to administration of a long-acting sub-cutaneous injection which is then administered every 6 months.

Lenacapavir is indicated in the European Union for the treatment of adults with multi-drug resistant HIV infection in combination with other antiretroviral(s), for whom it is otherwise not possible to construct a suppressive anti-viral regimen. A New Drug Application (NDA) has been submitted to the U.S. Food & Drug Administration (FDA) and is currently being considered.

Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016